NCT00220402View on ClinicalTrials.gov

Long-Term Open-Label Extension Trial for Subjects Completing the Phase 3 Trial of Fesoterodine (SP583) for the Treatment of Overactive Bladder Syndrome

PHASE3CompletedINTERVENTIONAL
Timeline

Start Date

July 31, 2004

Primary Completion Date

July 31, 2007

Study Completion Date

July 31, 2007

Conditions
Overactive Bladder Syndrome
Interventions
DRUG

SPM 907

Trial Locations (1)

Unknown

Schwarz, Monheim

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT00220402 - Long-Term Open-Label Extension Trial for Subjects Completing the Phase 3 Trial of Fesoterodine (SP583) for the Treatment of Overactive Bladder Syndrome | Biotech Hunter | Biotech Hunter